(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases...
Stats | |
---|---|
今日成交量 | 162 831 |
平均成交量 | 239 122 |
市值 | 3.61M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $-0.870 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0500 |
ATR14 | $0.00200 (0.63%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-19 | Murphy James B | Buy | 0 | |
2024-01-02 | Fortress Biotech, Inc. | Buy | 419 092 | COMMON STOCK, PAR VALUE $0.0001 |
2023-12-11 | Carney Peter | Sell | 0 | Common Stock |
2023-07-05 | Zelefsky Michael J | Buy | 7 246 | COMMON STOCK, PAR VALUE $0.0001 |
2023-07-05 | Chill Adam J. | Buy | 7 246 | COMMON STOCK, PAR VALUE $0.0001 |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 5 442 388 | Sell: 2 083 593 |
音量 相关性
Mustang Bio Inc 相关性 - 货币/商品
Mustang Bio Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-2.23M (0.00 %) |
EPS: | $-6.00 |
FY | 2023 |
营收: | $0 |
毛利润: | $-2.23M (0.00 %) |
EPS: | $-6.00 |
FY | 2022 |
营收: | $0 |
毛利润: | $-3.03M (0.00 %) |
EPS: | $-11.44 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.760 |
Financial Reports:
No articles found.
Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。